1160825-89-7

Basic information

• Product Name: ethyl 4-(4-(tert-butoxycarbonyl)amino-3-fluorophenoxy)-2-aminopyridin-3-yl-carbamate
• Synonyms: ethyl 4-(4-(tert-butoxycarbonyl)amino-3-fluorophenoxy)-2-aminopyridin-3-yl-carbamate
• CAS NO: 1160825-89-7
• Molecular Weight: 406.414
• Mol File: 1160825-89-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: ethyl 4-(4-(tert-butoxycarbonyl)amino-3-fluorophenoxy)-2-aminopyridin-3-yl-carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(4-(tert-butoxycarbonyl)amino-3-fluorophenoxy)-2-aminopyridin-3-yl-carbamate(1160825-89-7)
• EPA Substance Registry System: ethyl 4-(4-(tert-butoxycarbonyl)amino-3-fluorophenoxy)-2-aminopyridin-3-yl-carbamate(1160825-89-7)

Safety Data

• Hazardous Substances Data: 1160825-89-7(Hazardous Substances Data)

Upstream product

• 911297-02-4 N-(2-fluoro-4-hydroxyphenyl)carbamic acid tert-butyl ester 
• 1163720-60-2 4-(4-N-(tert-butoxycarbonyl)amino-3-fluorophenoxy)-3-nitro-2-aminopyridine 
• 399-95-1 4-amino-3-fluorophenol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1163720-66-8 4-(4-N-(tert-butoxycarbonyl)amino-3-fluorophenoxy)-2,3-diaminopyridine 
• 541-41-3 chloroformic acid ethyl ester 

Downstream Products

• 1160825-91-1 ethyl 4-(4-amino-3-fluorophenoxy)-2-aminopyridin-3-yl-carbamate 
• 1160825-93-3 ethyl (4-(4-amino-3-fluorophenoxy)-2-aminopyridin-3-yl)(methyl)carbamate 
• 1160825-67-1 7-(4-amino-3-fluorophenoxy)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one 
• 1321451-78-8 1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(1-N-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)phenyl)urea 
• 1321451-84-6 1-(3-tert-butyl-1-(3-fluorophenyl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)phenyl)urea 

Relevant articles and documents

1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL-2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRID1N-7-YLOXY)-PHENYL]-UREA AND RELATED COMPOUNDS AND THEIR USE IN THERAPY

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (I) (for convenience, collectively referred to herein as "IP compounds"), which, inter alia, are useful in